Table 2. Noncompartmental pharmacokinetic analysis results for 15 healthy subjects administered the MBT with and without Orlistat. tmax reported as the median and range.
| Treatment | Fat | C0
(mg/dl) |
tmax
(h) |
Cmax
(mg/dl) |
AUC (mg×h×dl–1) |
|
|---|---|---|---|---|---|---|
| None | HA | Mean | 0.979 | 5.5 | 11.2 | 36.4 |
| SD | 0.429 | [4 – 7] | 8.68 | 30.2 | ||
| 95% CI | (0.741, 1.22) | (6.38, 16.0) | (19.7, 53.2) | |||
| PA | Mean | 0.763 | 4 | 6.19 | 25.1 | |
| SD | 0.394 | [2 – 6] | 4.27 | 17.4 | ||
| 95% CI | (0.545, 0.981) | (3.83, 8.55) | (15.5, 34.7) | |||
| Orlistat | HA | Mean | 1.28 | 4.5 | 3.28 | 12.8 |
| SD | 0.340 | [3 – 6] | 2.44 | 8.54 | ||
| 95% CI | (1.07, 1.39) | (1.93, 4.64) | (8.03, 17.5) | |||
| PA | Mean | 1.02 | 4 | 5.26 | 21.6 | |
| SD | 0.674 | [2 - 6] | 3.14 | 11.8 | ||
| 95% CI | (0.646, 1.39) | (3.52, 6.99) | (15.1, 28.1) |